California based biotech company Isis Pharmaceuticals had been contemplating a name chance since the Paris terror attacks that took place in November. The company was wary of people and media wrongly associating them with the terrorist group ‘ISIS’. Company’s associate director of corporate communications Dr. Amy Williford said, “We wanted to have a good feeling associated with the company.” She mentioned that employee safety was a motivating factor behind the decision as well since scientists working with Ionis often travel to other countries.
Isis/Ionis was founded 30 years back and it deals in drugs for rare and critical diseases. Dr. Williford confirmed that the company will move to a new domain called ionispharma.com and will change its stock market ticker to ‘IONS’. Documents bearing the name of Isis will also be amended. Last month the VP of Corporate Communications D. Wade Walke hinted at the company looking for a new identity.